Literature DB >> 35325558

Structure-Function Relationships in the Rodent Streptozotocin-Induced Model for Diabetic Retinopathy: A Systematic Review.

Inesa Lelyte1,2, Zubair Ahmed2,3, Simon Kaja4,5, Giedrius Kalesnykas1,6.   

Abstract

The streptozotocin (STZ)-induced rodent model is one of the most commonly employed models in preclinical drug discovery for diabetic retinopathy (DR). However, standardization and validation of experimental readouts are largely lacking. The aim of this systematic review was to identify and compare the most useful readouts of STZ-induced DR and provide recommendations for future study design based on our findings. We performed a systematic search using 2 major databases, PubMed and EMBASE. Only articles describing STZ-induced DR describing both functional and structural readouts were selected. We also assessed the risk of bias and analyzed qualitative data in the selected studies. We identified 21 studies that met our inclusion/exclusion criteria, using either rats or mice and study periods of 2 to 24 weeks. Glucose level thresholds used to define hyperglycemia were inconsistent between studies, however, most studies used either 250 or 300.6 mg/dL as a defining criterion for hyperglycemia. All included studies performed electroretinography (ERG) and reported a reduction in a-, b-, or c-wave and/or oscillatory potential amplitudes. Spectral-domain optical coherence tomography and fluorescein angiography, as well as immunohistochemical and histopathological analyses showed reductions in retinal thickness, vascular changes, and presence of inflammation. Risk of bias assessment showed that all studies had a high risk of bias due to lack of reporting or correctly following procedures. Our systematic review highlights that ERG represents the most consistent functional readout in the STZ model. However, due to the high risk of bias, caution must be used when interpreting these studies.

Entities:  

Keywords:  diabetic retinopathy; electroretinogram; fluorescein angiography; glucose level; optical coherence tomography; streptozotocin

Mesh:

Substances:

Year:  2022        PMID: 35325558      PMCID: PMC9125572          DOI: 10.1089/jop.2021.0128

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.850


  55 in total

1.  Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus.

Authors:  P Carpineto; L Toto; R Aloia; V Ciciarelli; E Borrelli; E Vitacolonna; M Di Nicola; L Di Antonio; R Mastropasqua
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

2.  The welfare of animals used in science: how the "Three Rs" ethic guides improvements.

Authors:  Nicole Fenwick; Gilly Griffin; Clément Gauthier
Journal:  Can Vet J       Date:  2009-05       Impact factor: 1.008

3.  TLR7 deficiency contributes to attenuated diabetic retinopathy via inhibition of inflammatory response.

Authors:  Yun-Ru Liao; Zi-Jing Li; Peng Zeng; Yu-Qing Lan
Journal:  Biochem Biophys Res Commun       Date:  2017-08-24       Impact factor: 3.575

4.  Death of retinal neurons in streptozotocin-induced diabetic mice.

Authors:  Pamela M Martin; Penny Roon; Tracy K Van Ells; Vadivel Ganapathy; Sylvia B Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

5.  Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats.

Authors:  Irene Paterniti; Rosanna Di Paola; Michela Campolo; Rosalba Siracusa; Marika Cordaro; Giuseppe Bruschetta; Gemma Tremolada; Anna Maestroni; Francesco Bandello; Emanuela Esposito; Gianpaolo Zerbini; Salvatore Cuzzocrea
Journal:  Eur J Pharmacol       Date:  2015-11-27       Impact factor: 4.432

6.  Retrobulbarly injecting nerve growth factor attenuates visual impairment in streptozotocin-induced diabetes rats.

Authors:  Qi-Chang Wang; Wang Sheng; Cai-Jiao Yi; Han Lv; Bei Cheng
Journal:  Int Ophthalmol       Date:  2020-08-10       Impact factor: 2.031

7.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

Authors:  Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher
Journal:  BMJ       Date:  2021-03-29

Review 8.  The progress in understanding and treatment of diabetic retinopathy.

Authors:  Alan W Stitt; Timothy M Curtis; Mei Chen; Reinhold J Medina; Gareth J McKay; Alicia Jenkins; Thomas A Gardiner; Timothy J Lyons; Hans-Peter Hammes; Rafael Simó; Noemi Lois
Journal:  Prog Retin Eye Res       Date:  2015-08-18       Impact factor: 21.198

9.  Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes.

Authors:  Cristina Hernández; Marta García-Ramírez; Lidia Corraliza; Jimena Fernández-Carneado; Josep Farrera-Sinfreu; Berta Ponsati; Agueda González-Rodríguez; Angela M Valverde; Rafael Simó
Journal:  Diabetes       Date:  2013-03-08       Impact factor: 9.461

10.  Can allopurinol improve retinopathy in diabetic rats? Oxidative stress or uric acid; which one is the culprit?

Authors:  Mohsen Goharinia; Athar Zareei; Mansour Rahimi; Hossein Mirkhani
Journal:  Res Pharm Sci       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.